W. Meng

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132).

Steven A. Spronk, K. Behnia, J. Barrish, 2022, Journal of medicinal chemistry.

Structural characteristics, antioxidant properties and antiaging activities of galactan produced by Mentha haplocalyx Briq.

W. Meng, Lili Jiao, Peng Jiang, 2020, Carbohydrate polymers.

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

W. Humphreys, B. Koplowitz, A. Khanna, 2010, Drug Metabolism and Disposition.

Synthesis Optimization, Scale-Up, and Catalyst Screening Efforts toward the MGAT2 Clinical Candidate, BMS-963272

Lidet K. Negash, A. Mathur, R. Lawrence, 2022, Organic Process Research & Development.

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Li Xin, Joseph R. Taylor, Songping Han, 2008, Diabetes.

Residual Characteristics of Atrazine and Its Metabolites in the Liaoning Province of China

M. Ji, W. Meng, Hongzhe Tian, 2022, Separations.

The role of complex interactions between the intestinal flora and host in regulating intestinal homeostasis and inflammatory bowel disease

Minjian Chen, Guangcong Ruan, Lu Chen, 2023, Frontiers in Microbiology.

Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.

P. Gargalovic, D. Gordon, R. Wexler, 2021, ACS medicinal chemistry letters.